Avenue Therapeutics (ATXI) Competitors $0.35 -0.05 (-12.40%) As of 07/15/2025 03:42 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ATXI vs. MTNB, VIVS, RDHL, CNSP, DRMA, THAR, SNGX, SPRB, CMND, and REVBShould you be buying Avenue Therapeutics stock or one of its competitors? The main competitors of Avenue Therapeutics include Matinas Biopharma (MTNB), VivoSim Labs (VIVS), Redhill Biopharma (RDHL), CNS Pharmaceuticals (CNSP), Dermata Therapeutics (DRMA), Tharimmune (THAR), Soligenix (SNGX), Spruce Biosciences (SPRB), Clearmind Medicine (CMND), and Revelation Biosciences (REVB). These companies are all part of the "pharmaceutical products" industry. Avenue Therapeutics vs. Its Competitors Matinas Biopharma VivoSim Labs Redhill Biopharma CNS Pharmaceuticals Dermata Therapeutics Tharimmune Soligenix Spruce Biosciences Clearmind Medicine Revelation Biosciences Avenue Therapeutics (NASDAQ:ATXI) and Matinas Biopharma (NYSE:MTNB) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, profitability, risk, earnings and dividends. Is ATXI or MTNB more profitable? Matinas Biopharma's return on equity of -123.06% beat Avenue Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Avenue TherapeuticsN/A -471.57% -296.50% Matinas Biopharma N/A -123.06%-94.28% Which has preferable earnings & valuation, ATXI or MTNB? Matinas Biopharma is trading at a lower price-to-earnings ratio than Avenue Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAvenue TherapeuticsN/AN/A-$10.38M-$7.49-0.05Matinas BiopharmaN/AN/A-$22.94M-$3.86-0.26 Which has more risk & volatility, ATXI or MTNB? Avenue Therapeutics has a beta of -0.08, suggesting that its stock price is 108% less volatile than the S&P 500. Comparatively, Matinas Biopharma has a beta of 1.31, suggesting that its stock price is 31% more volatile than the S&P 500. Do analysts rate ATXI or MTNB? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avenue Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Matinas Biopharma 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the media favor ATXI or MTNB? In the previous week, Avenue Therapeutics had 5 more articles in the media than Matinas Biopharma. MarketBeat recorded 5 mentions for Avenue Therapeutics and 0 mentions for Matinas Biopharma. Matinas Biopharma's average media sentiment score of 0.00 beat Avenue Therapeutics' score of -0.44 indicating that Matinas Biopharma is being referred to more favorably in the news media. Company Overall Sentiment Avenue Therapeutics Neutral Matinas Biopharma Neutral Do insiders & institutionals believe in ATXI or MTNB? 17.3% of Avenue Therapeutics shares are owned by institutional investors. Comparatively, 11.8% of Matinas Biopharma shares are owned by institutional investors. 1.8% of Avenue Therapeutics shares are owned by insiders. Comparatively, 4.6% of Matinas Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. SummaryMatinas Biopharma beats Avenue Therapeutics on 7 of the 11 factors compared between the two stocks. Get Avenue Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATXI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ATXI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATXI vs. The Competition Export to ExcelMetricAvenue TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.12M$724.81M$5.61B$9.30BDividend YieldN/A4.84%4.23%4.03%P/E Ratio0.021.1828.5219.58Price / SalesN/A25.52426.1793.37Price / CashN/A19.5636.0257.93Price / Book0.186.918.135.54Net Income-$10.38M-$4.17M$3.24B$257.73M7 Day Performance50.19%1.41%0.20%-0.08%1 Month Performance62.90%1.34%5.98%8.09%1 Year Performance-90.29%7.45%26.15%13.02% Avenue Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATXIAvenue Therapeutics2.0107 of 5 stars$0.35-12.4%N/A-89.9%$1.12MN/A0.024Gap UpMTNBMatinas BiopharmaN/A$1.00-2.9%N/AN/A$5.09MN/A-0.2130VIVSVivoSim LabsN/A$1.94+0.0%N/AN/A$5.04M$140K-0.1920Positive NewsRDHLRedhill BiopharmaN/A$2.18-0.5%N/A-99.2%$5.00M$8.04M0.00210Positive NewsCNSPCNS Pharmaceuticals2.1249 of 5 stars$0.88+0.1%$25.00+2,755.5%-98.5%$4.78MN/A0.005DRMADermata Therapeutics2.1963 of 5 stars$0.73+2.7%$3.00+311.5%-66.7%$4.65MN/A-0.048THARTharimmune3.3121 of 5 stars$1.69-2.3%$17.00+905.9%-58.7%$4.50MN/A-0.212Positive NewsSNGXSoligenix0.976 of 5 stars$1.36+7.1%N/A-81.8%$4.44M-$117.03K-0.3220SPRBSpruce Biosciences2.0491 of 5 stars$0.10+15.3%$1.75+1,597.4%-83.3%$4.35M$4.91M-0.1120Gap DownCMNDClearmind Medicine0.9147 of 5 stars$0.99+4.0%N/A-56.2%$4.22MN/A-0.90N/APositive NewsREVBRevelation Biosciences0.9434 of 5 stars$2.75-1.4%N/A-96.8%$4.21MN/A-0.0110 Related Companies and Tools Related Companies Matinas Biopharma Alternatives VivoSim Labs Alternatives Redhill Biopharma Alternatives CNS Pharmaceuticals Alternatives Dermata Therapeutics Alternatives Tharimmune Alternatives Soligenix Alternatives Spruce Biosciences Alternatives Clearmind Medicine Alternatives Revelation Biosciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ATXI) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avenue Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avenue Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ATXI Stock Alerts